Related Experiment Video
Updated: May 22, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B
Suparna Mazumder1, Gaurav S Choudhary, Sayer Al-Harbi
1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Ohio 44195, USA.
Abstract:
ABT-737 is a small molecule Bcl-2 homology (BH)-3 domain mimetic that binds to the Bcl-2 family proteins Bcl-2 and Bcl-xL and is currently under investigation in the clinic. In this study, we investigated potential mechanisms of resistance to ABT-737 in leukemia cell lines. Compared with parental cells, cells that have developed acquired resistance to ABT-737 showed increased expression of Mcl-1 in addition to posttranslational modifications that facilitated both Mcl-1 stabilization and its interaction with the BH3-only protein Bim. To sensitize resistant cells, Mcl-1 was targeted by two pan-Bcl-2 family inhibitors, obatoclax and gossypol. Although gossypol was effective only in resistant cells, obatoclax induced cell death in both parental and ABT-737-resistant cells. NOXA levels were increased substantially by treatment with gossypol and its expression was critical for the gossypol response. Mechanistically, the newly generated NOXA interacted with Mcl-1 and displaced Bim from the Mcl-1/Bim complex, freeing Bim to trigger the mitochondrial apoptotic pathway. Together, our findings indicate that NOXA and Mcl-1 are critical determinants for gossypol-mediated cell death in ABT-737-resistant cells. These data therefore reveal novel insight into mechanisms of acquired resistance to ABT-737.
Insights
Resistance to ABT-737 in leukemia involves increased Mcl-1. Targeting Mcl-1 with gossypol or obatoclax can overcome this resistance, with NOXA being crucial for gossypol
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- ABT-737, a Bcl-2 homology (BH)-3 domain mimetic, targets Bcl-2 and Bcl-xL proteins.
- Understanding resistance mechanisms to ABT-737 is crucial for leukemia treatment.
Purpose of the Study:
- Investigate mechanisms of acquired resistance to ABT-737 in leukemia cell lines.
- Evaluate Mcl-1 targeting agents (obatoclax, gossypol) for overcoming ABT-737 resistance.
Main Methods:
- Developed ABT-737-resistant leukemia cell lines.
- Analyzed Mcl-1 expression and posttranslational modifications.
- Assessed responses to obatoclax and gossypol, including NOXA and Bim interactions.
Main Results:
- Resistant cells exhibited increased Mcl-1 stabilization and interaction with Bim.
- Gossypol specifically sensitized resistant cells, dependent on NOXA induction.
- Obatoclax induced cell death in both parental and resistant cells.
Conclusions:
- NOXA and Mcl-1 are key mediators of gossypol-induced cell death in ABT-737-resistant leukemia.
- Targeting Mcl-1 offers a strategy to overcome ABT-737 resistance.
- Findings provide novel insights into acquired resistance mechanisms to BH-3 mimetics.
Related Concept Videos
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

